76 related articles for article (PubMed ID: 28131770)
1. Dopamine D3 receptor-modulated neuroprotective effects of lisuride.
Kim M; Lee S; Cho J; Kim G; Won C
Neuropharmacology; 2017 May; 117():14-20. PubMed ID: 28131770
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
Kim MK; Park HS; Cho JH; Kim GS; Won C
Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
Collo G; Zanetti S; Missale C; Spano P
Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
5. Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture.
Moldzio R; Radad K; Duvigneau JC; Kranner B; Krewenka C; Piskernik C; Rausch WD
J Neural Transm (Vienna); 2006 Sep; 113(9):1095-105. PubMed ID: 16463121
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
8. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
9. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Le WD; Jankovic J; Xie W; Appel SH
J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
[TBL] [Abstract][Full Text] [Related]
12. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.
Das B; Rajagopalan S; Joshi GS; Xu L; Luo D; Andersen JK; Todi SV; Dutta AK
Neuropharmacology; 2017 Sep; 123():88-99. PubMed ID: 28533164
[TBL] [Abstract][Full Text] [Related]
13. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
14. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
[TBL] [Abstract][Full Text] [Related]
15. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
16. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration.
Double KL; Halliday GM; Henderson J; Griffiths FM; Heinemann T; Riederer P; Gerlach M
Exp Neurol; 2003 Nov; 184(1):530-5. PubMed ID: 14637122
[TBL] [Abstract][Full Text] [Related]
17. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.
Newton CL; Wood MD; Strange PG
PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
[TBL] [Abstract][Full Text] [Related]
19. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
20. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
